The Apathy in Dementia Methylphenidate Trial (ADMET) is a masked, placebo-controlled trial
that will examine the efficacy and safety of methylphenidate for the treatment of clinically
significant apathy in patients with Alzheimer's dementia.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins Bloomberg School of Public Health
Collaborators:
Johns Hopkins University Medical University of South Carolina National Institute on Aging (NIA) University of Toronto